Stock listing
EGTXS Stock Price, News, Filings & Events — Egetis Therapeutics Ab
Selected listing: EGTXS · AQUISUK · SEK · GB
This page tracks Egetis Therapeutics Ab's EGTXS:AQUISUK listing on AQUISUK in SEK for GB, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following EGTXS:AQUISUK. EGTXS:AQUISUK is the stock-level entry point for investors researching Egetis Therapeutics Ab, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
- Ticker
- EGTXS:AQUISUK
- Asset type
- Stock
- Market cap
- $332.0M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- AQUISUK
- Currency
- SEK
Egetis Therapeutics Ab EGTXS:AQUISUK stock context
This page tracks Egetis Therapeutics Ab's EGTXS:AQUISUK listing on AQUISUK in SEK for GB, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following EGTXS:AQUISUK. EGTXS:AQUISUK is the stock-level entry point for investors researching Egetis Therapeutics Ab, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
Latest news from Egetis Therapeutics Ab
Egetis Announces Grant of Patent for MCT8 Deficiency Composition in The U.S.
May 5, 2026
Egetis Appoints Tiago Nunes as Chief Medical Officer
April 9, 2026
Egetis Announces FDA Acceptance and Priority Review of NDA for Emcitate(R) (tiratricol) for MCT8 Deficiency
March 27, 2026
Egetis Receives Notice of Allowance for MCT8 Deficiency Composition Patent in the U.S.
March 9, 2026
Egetis Therapeutics Launches Educational Websites on MCT8 Deficiency for Physicians and Caregivers
March 2, 2026
Egetis Therapeutics Ab earnings calls
Research Egetis Therapeutics Ab
Egetis Therapeutics Ab investor report
Review AI stock analysis and investor report context for EGTXS:AQUISUK.
Egetis Therapeutics Ab company profile
View the public company page for Egetis Therapeutics Ab on 6ix.
Egetis Therapeutics Ab news
Read company news and market updates connected to Egetis Therapeutics Ab.
Egetis Therapeutics Ab investor events
Find investor webinars, events, and replay context for Egetis Therapeutics Ab.
Alternate listings
EGTX:OMXSTO
SE · SEK
Alternate listing for Egetis Therapeutics Ab; the primary context on this page is EGTXS:AQUISUK.
0ABW:LSE
GB · SEK
Alternate listing for Egetis Therapeutics Ab; the primary context on this page is EGTXS:AQUISUK.
PDPHF:OTC
US · USD
Alternate listing for Egetis Therapeutics Ab; the primary context on this page is EGTXS:AQUISUK.
A1JH3B:LS
DE · EUR
Alternate listing for Egetis Therapeutics Ab; the primary context on this page is EGTXS:AQUISUK.
A1JH3B:LSX
DE · EUR
Alternate listing for Egetis Therapeutics Ab; the primary context on this page is EGTXS:AQUISUK.
P0F:FWB
DE · EUR
Alternate listing for Egetis Therapeutics Ab; the primary context on this page is EGTXS:AQUISUK.
P0F:GETTEX
DE · EUR
Alternate listing for Egetis Therapeutics Ab; the primary context on this page is EGTXS:AQUISUK.
EGTXS:AQUISEU
GB · SEK
Alternate listing for Egetis Therapeutics Ab; the primary context on this page is EGTXS:AQUISUK.
P0F:MUN
DE · EUR
Alternate listing for Egetis Therapeutics Ab; the primary context on this page is EGTXS:AQUISUK.
P0F:SWB
DE · EUR
Alternate listing for Egetis Therapeutics Ab; the primary context on this page is EGTXS:AQUISUK.